4-fluorobenzyl chloroformate | 105416-91-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-fluorobenzyl chloroformate
• 英文别名: p-Fluorobenzyl chloroformate；(4-fluorophenyl)methyl carbonochloridate
• CAS: 105416-91-9
• 化学式: C₈H₆ClFO₂
• 分子量: 188.586
• InChiKey: CNDKJCOMEMJVKI-UHFFFAOYSA-N

物化性质

• 沸点：
  230.1±23.0 °C(Predicted)
• 密度：
  1.334±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-fluorobenzyl chloroformate 在 4-二甲氨基吡啶 、 sodium hydroxide 、 1-羟基苯并三唑 、 戴斯-马丁氧化剂 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 生成 5-Fluoro-3-[(S)-2-(4-fluoro-benzyloxycarbonylamino)-3-methyl-butyrylamino]-4-oxo-pentanoic acid
  参考文献：
  名称：

  Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: SAR of the N-protecting group

  摘要：

  This article describes the synthesis and biological evaluation of a group of N-protected Val-Asp-fmk as caspase inhibitors. The protecting group was found to contribute to caspase-3 inhibiting activity, and compounds with a large group such as Cbz are more active than compounds with a small group such as Ac. Compounds with more hydrophobic protecting groups were found to be more active in cell apoptosis protection assays, probably due to increased cell permeability. MX1122,2,4-di-Cl-Cbz-Val-Aspfmk, is identified as a potent broad-spectrum caspase inhibitor and is selective for caspases versus other proteases, with good activity in the cell apoptosis protection assays as well as good efficacy in the mouse liver apoptosis model. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.08.027
• 作为产物：
  描述：

  (4-Fluorophenyl)methyl hydrogen carbonate 在 氯化亚砜 作用下， 反应 3.0h， 生成 4-fluorobenzyl chloroformate
  参考文献：
  名称：

  Phenylalanine derivatives enhancing intestinal absorption of insulin in mice.

  摘要：

  研究了N-酰基-L-和D-苯丙氨酸衍生物对正常小鼠胰岛素肠道吸收的辅助效应。根据小鼠口服胰岛素和辅料联合给药后的血糖浓度和胰岛素水平，推测了N-酰基部分的化学结构性质与促吸收活性之间的相关性。N-酰基-苯丙氨酸衍生物对胰岛素肠道吸收具有辅效应的化学结构性质如下：1. 芳环存在，与酰基羰基相隔两个原子。2. 图2中的X或Y之一为氧，或者X-Y是双键。3. N-酰基部分具有较小的疏水取代基，如F、Cl或Me在Rα、Rβ、Rη位置，并且整个分子具有适当的亲水-疏水平衡。利用这些制剂增强胰岛素吸收，为口服胰岛素治疗提供了新的途径。

  DOI：

  10.1248/cpb.36.4426

文献信息

• Deoxygenative cross-electrophile coupling of benzyl chloroformates with aryl iodides
  作者：Yingying Pan、Yuxin Gong、Yanhong Song、Weiqi Tong、Hegui Gong

  DOI：10.1039/c9ob00628a

  日期：——

  This work describes Ni-catalyzed cross-electrophile coupling of benzyl chloroformate derivatives with aryl iodides that generates a wide range of diaryl methane products. The mild reaction conditions merit the C–O bond radical fragmentation of benzyl chloroformates via halide abstraction or a single electron reduction by a Ni catalyst. This work offers a new substrate type for cross-electrophile couplings

  这项工作描述了镍催化的氯甲酸苄酯衍生物与芳基碘化物的交叉亲电子偶联，生成多种二芳基甲烷产物。温和的反应条件使得氯甲酸苄酯的 C-O 键自由基通过卤化物夺取或 Ni 催化剂的单电子还原而断裂。这项工作为交叉亲电子偶联提供了一种新的底物类型。
• PYRROLIDINE DERIVATIVES AS PPAR AGONISTS
  申请人：GUANGDONG RAYNOVENT BIOTECH CO., LTD.

  公开号：US20190225597A1

  公开（公告）日：2019-07-25

  The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholgangitis, dyslipidenmia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

  本发明公开了一类吡咯烷衍生物作为PPAR激动剂，并其用于治疗PPAR受体相关途径的一些疾病（如非酒精性脂肪肝和伴发纤维化、胰岛素抵抗、原发性胆管炎、血脂异常、高脂血症、高胆固醇血症、动脉粥样硬化、高甘油三酯血症、心血管疾病、肥胖或类似疾病）。具体而言，本发明公开了由式（I）表示的化合物或其药学上可接受的盐。
• [EN] PTH AGONISTS<br/>[FR] AGONISTES DE PTH
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005077918A1

  公开（公告）日：2005-08-25

  This invention relates to uracil-derived compounds of forumlas(I) and (II) which are agonists of the parathyroid hormone type I receptor (PTH1R) and as such are useful for the treament of osteoporosis.

  这项发明涉及到式(I)和(II)的尿嘧啶衍生物，这些衍生物是甲状旁腺激素类型I受体（PTH1R）的激动剂，因此对于骨质疏松症的治疗是有用的。
• Pharmaceutical use of derivatives of tryptophan
  申请人：Rotta Research Laboratorium S.p.A.

  公开号：US04870097A1

  公开（公告）日：1989-09-26

  N-acylated derivatives of L-tryptophan of general formula (I), ##STR1## in which R is selected from the group consisting of: (a) a phenyl group, mono-substituted or di-substituted in the meta and para positions with halogens, linear or branched alkyl groups containing from 1 to 9 carbon atoms, the cyano group or the trifluoromethyl group, (b) a benzyloxy group, mono-substituted or di-substituted in the meta and para position with substituents selected from those indicated at (a), and (c) a benzydryloxy group. The derivatives are used in therapy, particularly for human pain relief, in the treatment of pathological conditions of the central nervous system and of pathological intestinal conditions.

  通用式（I）的N-酰化L-色氨酸衍生物，其中R从以下组中选择：（a）苯基，间位和对位与卤素、含有1至9个碳原子的直链或支链烷基基团、氰基或三氟甲基基团单取代或双取代的苯基，（b）苄氧基，间位和对位与从（a）中指示的取代基中选择的取代基单取代或双取代的苄氧基，以及（c）苄基氧基。这些衍生物用于治疗，特别是用于人类疼痛缓解，治疗中枢神经系统和肠道病理状况。
• Synthesis and Antifungal Activity of Some 6-tert-butyl-8-chloro-2, 3-dimethylquinolin-4-ol Derivatives against Pyricularia oryae
  作者：Yue-Ming Fang、Rui-Rui Zhang、Zhong-Hua Shen、Cheng-Xia Tan、Jian-Quan Weng、Tian-Ming Xu、Xing-Hai Liu、Hong-Ying Huang、Hong-Ke Wu

  DOI：10.2174/1570180815666180313121735

  日期：2018.12

  Background: A series of new 6-(tert-butyl)-8-chloro-2,3-dimethyl quinoline derivatives were designed and synthesized. Results: The primarily antifungal assay results indicated that all of them exhibited excellent protective efficacy (100%) against Pyricularia oryae at 100 ppm, except compound 2m (90%). Among them, the compound 2p (6-(tert-butyl)-8-chloro-2,3-dimethylquinolin-4-yl(2-chloro-5- (trif

  背景：设计并合成了一系列新的6-（叔丁基）-8-氯-2,3-二甲基喹啉衍生物。 结果：主要的抗真菌分析结果表明，除化合物2m（90％）外，所有化合物均在100 ppm时对稻瘟病菌表现出极好的保护效果（100％）。其中，化合物2p（6-（叔丁基）-8-氯-2,3-二甲基喹啉-4-基（2-氯-5-（三氟甲基）苄基）碳酸酯）对稻瘟病菌的杀真菌效果最高。 ，即使是10 ppm。 结论：构效关系表明，当苯环的2位被F或Cl取代时，该化合物对稻瘟病菌具有良好的抗真菌活性。